• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 4 filed by Chief Financial Officer Tsimerman Ronen

    5/18/26 8:01:20 AM ET
    $ICCM
    Medical/Dental Instruments
    Health Care
    Get the next $ICCM alert in real time by email
    SEC FORM 4SEC Form 4
    FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number:3235-0287
    Estimated average burden
    hours per response:0.5
    X
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Tsimerman Ronen

    (Last)(First)(Middle)
    7 HA'ESHEL ST., PO BOX 3163

    (Street)
    CAESAREA3079504

    (City)(State)(Zip)

    ISRAEL

    (Country)
    2. Issuer Name and Ticker or Trading Symbol
    IceCure Medical Ltd. [ ICCM ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    Director10% Owner
    XOfficer (give title below)Other (specify below)
    Chief Financial Officer
    2a. Foreign Trading Symbol
    3. Date of Earliest Transaction (Month/Day/Year)
    05/17/2026
    6. Individual or Joint/Group Filing (Check Applicable Line)
    XForm filed by One Reporting Person
    Form filed by More than One Reporting Person
    4. If Amendment, Date of Original Filed (Month/Day/Year)

    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    CodeVAmount(A) or (D)Price
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
    Explanation of Responses:
    Remarks:
    This Exit Form 4 has been filed solely to report that Reporting Person ceased to serve as the Chief Financial Officer of IceCure Medical Ltd (the "Issuer") on May 17, 2026 and is no longer subject to the reporting obligations under Section 16 of the Securities Exchange Act of 1934, as amended, with respect to the Issuer.
    /s/ Ronen Tsimerman05/18/2026
    ** Signature of Reporting PersonDate
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    * Form 4: SEC 1474 (03-26)
    Get the next $ICCM alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ICCM

    DatePrice TargetRatingAnalyst
    2/2/2022$5.65Buy
    Brookline Capital
    9/22/2021$14.50Buy
    Alliance Global Partners
    More analyst ratings

    $ICCM
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    IceCure Highlights New Peer-Reviewed Journal Article in Leading Surgery Journal, Demonstrating Cryoablation's Advantages Over Radiofrequency Ablation for Early-Stage Breast Cancer

    Published in the International Journal of Surgery, globally ranked in the top three among surgery journals, the article highlights strong clinical outcomes with ProSense® cryoablation and describes thermal ablation as a "beacon of hope for patients IceCure preparing for the 2026 Japanese Breast Cancer Society meeting and planned regulatory submission for breast cancer in Japan by Terumo Corporation one of the world's top 20 medical device companiesCAESAREA, Israel, June 23, 2026 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ:ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an option to surgical tu

    6/23/26 8:10:00 AM ET
    $ICCM
    Medical/Dental Instruments
    Health Care

    IceCure Announces Pricing of $5.5 Million Private Placement Priced At a Premium to the Market Price with a Single Healthcare Focused Institutional Investor

    CAESAREA, Israel, June 17, 2026 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ:ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an option to surgical tumor removal, today announced that it has entered into securities purchase agreements with a single healthcare focused institutional investor, for the purchase and sale of 1,833,334 ordinary shares (or ordinary share equivalents in lieu thereof), Series D Warrants to purchase up to 1,833,334 ordinary shares (the "Series D Warrants") and Series E Warrants to purchase up to 1,833,334 ordinary shares (the "Series E Warrants," and together with the Seri

    6/17/26 1:14:00 PM ET
    $ICCM
    Medical/Dental Instruments
    Health Care

    Biotech's New Frontier: Companies Breaking Through Medicine's Toughest Barriers

    DENVER, June 17, 2026 (GLOBE NEWSWIRE) -- (247marketnews.com) – The biotechnology space is delivering a steady stream of potentially market-moving developments this week as companies across oncology, neuroscience, gene therapy, medical devices, and synthetic biology delivered significant regulatory, clinical, and commercial updates. NeOnc Technologies Holdings Advances Toward Critical Neuro-Oncology Milestones NeOnc (NASDAQ:NTHI) is becoming one of the more closely watched emerging neuro-oncology companies after securing a significant international regulatory milestone. The Department of Health – Abu Dhabi granted Investigational New Drug (IND) authorization for NEO212, the company's ora

    6/17/26 10:37:33 AM ET
    $CLPT
    $ICCM
    $NTHI
    Medical/Dental Instruments
    Health Care
    Biotechnology: Pharmaceutical Preparations

    $ICCM
    SEC Filings

    View All

    SEC Form 6-K filed by IceCure Medical Ltd.

    6-K - IceCure Medical Ltd. (0001584371) (Filer)

    6/18/26 4:47:30 PM ET
    $ICCM
    Medical/Dental Instruments
    Health Care

    SEC Form 6-K filed by IceCure Medical Ltd.

    6-K - IceCure Medical Ltd. (0001584371) (Filer)

    6/2/26 8:45:20 AM ET
    $ICCM
    Medical/Dental Instruments
    Health Care

    SEC Form 6-K filed by IceCure Medical Ltd.

    6-K - IceCure Medical Ltd. (0001584371) (Filer)

    5/19/26 8:45:22 AM ET
    $ICCM
    Medical/Dental Instruments
    Health Care

    $ICCM
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by VP, R&D & Engineering Muchnik Naum

    4 - IceCure Medical Ltd. (0001584371) (Issuer)

    5/18/26 8:01:55 AM ET
    $ICCM
    Medical/Dental Instruments
    Health Care

    New insider Peleg Meir claimed ownership of 400,000 units of Ordinary shares (SEC Form 3)

    3 - IceCure Medical Ltd. (0001584371) (Issuer)

    5/18/26 8:00:34 AM ET
    $ICCM
    Medical/Dental Instruments
    Health Care

    SEC Form 4 filed by Chief Financial Officer Tsimerman Ronen

    4 - IceCure Medical Ltd. (0001584371) (Issuer)

    5/18/26 8:01:20 AM ET
    $ICCM
    Medical/Dental Instruments
    Health Care

    $ICCM
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Brookline Capital initiated coverage on Icecure Medical with a new price target

    Brookline Capital initiated coverage of Icecure Medical with a rating of Buy and set a new price target of $5.65

    2/2/22 11:13:08 AM ET
    $ICCM
    Medical/Dental Instruments
    Health Care

    Alliance Global Partners initiated coverage on Icecure Medical with a new price target

    Alliance Global Partners initiated coverage of Icecure Medical with a rating of Buy and set a new price target of $14.50

    9/22/21 8:10:09 AM ET
    $ICCM
    Medical/Dental Instruments
    Health Care

    $ICCM
    Financials

    Live finance-specific insights

    View All

    IceCure Reports First Quarter 2026 Financial Results: ProSense® Sales Increase Substantially in the U.S. and North America

    Pent-up demand immediately following FDA clearance generates 46% increase in active customer accounts using ProSense® as of the end of the first quarter 2026, compared with prior to FDA clearanceAccelerating adoption of ProSense® driven by several growth catalysts, including FDA clearance, expanding reimbursement framework, media coverage, growing body of clinical data and recommendation of cryoablation for breast cancer in leading clinical guidelinesConference call to be held today at 11:00 am Eastern TimeCAESAREA, Israel, May 12, 2026 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ:ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology t

    5/12/26 8:30:00 AM ET
    $ICCM
    Medical/Dental Instruments
    Health Care

    IceCure Participates in Society of Breast Imaging Symposium 2026 as U.S. ProSense® Revenue Increases by 30%+ in First Quarter of 2026 Compared to First Quarter of 2025

    The Company's participation at the Society of Breast Imaging Symposium and other upcoming medical conferences are timely as commercial momentum acceleratesCryoablation cost analysis study from Massachusetts General Hospital featuring ProSense® demonstrated 50% reduction in cost vs. lumpectomy won SBI 2026 Abstract AwardCAESAREA, Israel, April 21, 2026 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ:ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an option to surgical tumor removal, today announced that it expects to report U.S. revenue of ProSense® systems and cryoprobes increased more than 30% in

    4/21/26 8:30:00 AM ET
    $ICCM
    Medical/Dental Instruments
    Health Care

    IceCure Reports 2025 Full Year Financial & Operational Results

    Record 4th quarter and full year sales of $1.3 million and $3.4 million, respectivelyStrong commercial momentum for ProSense® in the U.S. and globally following FDA clearance in low-risk breast cancer and medical society recommendations 30 hybrid commercial-clinical sites to be added for FDA approved post-marketing study in addition to growing pipeline of potential commercial customersIceCure Applies to Expand Regulatory Approval in Canada for ProSense® Cryoablation to Include the Treatment of Low-Risk Breast Cancer  Conference call to be held today at 11:00 am Eastern TimeCAESAREA, Israel, March 17, 2026 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ:ICCM) ("IceCure", "IceCure Medical" or the

    3/17/26 8:30:00 AM ET
    $ICCM
    Medical/Dental Instruments
    Health Care

    $ICCM
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by IceCure Medical Ltd.

    SC 13G/A - IceCure Medical Ltd. (0001584371) (Subject)

    11/14/24 9:38:43 PM ET
    $ICCM
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G/A filed by IceCure Medical Ltd. (Amendment)

    SC 13G/A - IceCure Medical Ltd. (0001584371) (Subject)

    2/14/23 8:46:31 AM ET
    $ICCM
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G/A filed by IceCure Medical Ltd. (Amendment)

    SC 13G/A - IceCure Medical Ltd. (0001584371) (Subject)

    1/24/23 5:04:22 PM ET
    $ICCM
    Medical/Dental Instruments
    Health Care

    $ICCM
    Leadership Updates

    Live Leadership Updates

    View All

    IceCure Appoints Meir Peleg as Chief Financial Officer

    Meir Peleg brings over 20 years of financial leadership and experience including with Nasdaq listed companiesIceCure intends to appoint Dr. Richard Fine as Medical Director CAESAREA, Israel, March 24, 2026 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ:ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an option to surgical tumor removal, today announced the appointment of Mr. Meir Peleg as its Chief Financial Officer ("CFO"), effective May 17, 2026. The appointment comes as IceCure is

    3/24/26 8:30:00 AM ET
    $ICCM
    Medical/Dental Instruments
    Health Care

    IceCure Announces Planned Departure of CFO Following Nine Years of Service and Key Milestones Achieved

    Ronen Tsimerman will continue as CFO until successor is appointed CAESAREA, Israel, Feb. 9, 2026 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ:ICCM) ("IceCure", "IceCure Medical" or the "Company"), a developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an option to surgical tumor removal, today announced that after nearly a decade of service with IceCure, Chief Financial Officer Ronen Tsimerman has informed the Company of his decision to leave the Company to pursue new opportunities. The Company has initiated a search for a new Chief Financial Officer and has identified compelling candidates with significant experience commercializing disruptive technolo

    2/9/26 4:30:00 PM ET
    $ICCM
    Medical/Dental Instruments
    Health Care

    IceCure Medical Takes Next Major Initiative as it Prepares to Accelerate the Commercialization of ProSense in U.S. and Canada: Appoints VP of Sales, North America

    Mr. Shad Good brings nearly 20 years of medical device sales and leadership experience, including as U.S. Senior Director of Sales at a global leader in minimally invasive breast diagnostic and therapeutic systemsImmediate responsibility is to build out the sales infrastructure as the Company awaits the FDA response to its regulatory filing for early-stage low risk breast cancer in patients who are at high risk for surgery as well as the FDA's response to the final ICE3 results which are due in 2024 CAESAREA, Israel, Aug. 28, 2023 /PRNewswire/ -- IceCure Medical Ltd. ("IceCure" or the "Company") (NASDAQ:ICCM) developer of the ProSense® System, a minimally-invasive cryoablation technology tha

    8/28/23 8:00:00 AM ET
    $ICCM
    Medical/Dental Instruments
    Health Care